Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 25 entries
Sorted by: Best Match Show Resources per page
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.

Cancer medicine

Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J.
PMID: 29436178
Cancer Med. 2018 Mar;7(3):746-756. doi: 10.1002/cam4.1372. Epub 2018 Feb 13.

Microsatellite instability (MSI) testing identifies patients who may benefit from immune checkpoint inhibitors. We developed an MSI assay that uses data from a commercially available next-generation sequencing (NGS) panel to determine MSI status. The assay is applicable across cancer...

Cite
Vanderwalde A, Spetzler D, Xiao N, et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018;7(3):746-756doi: 10.1002/cam4.1372.
Vanderwalde, A., Spetzler, D., Xiao, N., Gatalica, Z., & Marshall, J. (2018). Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer medicine, 7(3), 746-756. https://doi.org/10.1002/cam4.1372
Vanderwalde, Ari, et al. "Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients." Cancer medicine vol. 7,3 (2018): 746-756. doi: https://doi.org/10.1002/cam4.1372
Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018 Mar;7(3):746-756. doi: 10.1002/cam4.1372. Epub 2018 Feb 13. PMID: 29436178; PMCID: PMC5852359.
Copy Download .nbib Format: NLM
Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer.

Journal of breast cancer

Lee SE, Park HY, Lim SD, Han HS, Yoo YB, Kim WS.
PMID: 32595992
J Breast Cancer. 2020 Jun 01;23(3):303-313. doi: 10.4048/jbc.2020.23.e37. eCollection 2020 Jun.

PURPOSE: Triple-negative breast cancer (TNBC) represents a major clinical challenge due to its aggressive and metastatic behavior and the lack of available targeted therapies. Therefore, therapeutic strategies are needed to improve TNBC patient management. Recently, atezolizumab and nab-paclitaxel chemotherapy...

Cite
Lee SE, Park HY, Lim SD, et al. Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer. J Breast Cancer. 2020;23(3):303-313doi: 10.4048/jbc.2020.23.e37.
Lee, S. E., Park, H. Y., Lim, S. D., Han, H. S., Yoo, Y. B., & Kim, W. S. (2020). Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer. Journal of breast cancer, 23(3), 303-313. https://doi.org/10.4048/jbc.2020.23.e37
Lee, Seung Eun, et al. "Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer." Journal of breast cancer vol. 23,3 (2020): 303-313. doi: https://doi.org/10.4048/jbc.2020.23.e37
Lee SE, Park HY, Lim SD, Han HS, Yoo YB, Kim WS. Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer. J Breast Cancer. 2020 Jun 01;23(3):303-313. doi: 10.4048/jbc.2020.23.e37. eCollection 2020 Jun. PMID: 32595992; PMCID: PMC7311361.
Copy Download .nbib Format: NLM
Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity.

Journal for immunotherapy of cancer

Taki S, Matsuoka K, Nishinaga Y, Takahashi K, Yasui H, Koike C, Shimizu M, Sato M, Sato K.
PMID: 34725216
J Immunother Cancer. 2021 Oct;9(11). doi: 10.1136/jitc-2021-003036.

BACKGROUND: Near-infrared photoimmunotherapy (NIR-PIT) is a new modality for treating cancer, which uses antibody-photoabsorber (IRDye700DX) conjugates that specifically bind to target tumor cells. This conjugate is then photoactivated by NIR light, inducing rapid necrotic cell death. NIR-PIT needs a...

Cite
Taki S, Matsuoka K, Nishinaga Y, et al. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity. J Immunother Cancer. 2021;9(11)doi: 10.1136/jitc-2021-003036.
Taki, S., Matsuoka, K., Nishinaga, Y., Takahashi, K., Yasui, H., Koike, C., Shimizu, M., Sato, M., & Sato, K. (2021). Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity. Journal for immunotherapy of cancer, 9(11), . https://doi.org/10.1136/jitc-2021-003036
Taki, Shunichi, et al. "Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity." Journal for immunotherapy of cancer vol. 9,11 (2021). doi: https://doi.org/10.1136/jitc-2021-003036
Taki S, Matsuoka K, Nishinaga Y, Takahashi K, Yasui H, Koike C, Shimizu M, Sato M, Sato K. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity. J Immunother Cancer. 2021 Oct;9(11). doi: 10.1136/jitc-2021-003036. PMID: 34725216; PMCID: PMC8559243.
Copy Download .nbib Format: NLM
miR-195/miR-497 Regulate .

Journal of breast cancer

Yang L, Cai Y, Zhang D, Sun J, Xu C, Zhao W, Jiang W, Pan C.
PMID: 30607158
J Breast Cancer. 2018 Dec;21(4):371-381. doi: 10.4048/jbc.2018.21.e60. Epub 2018 Dec 26.

PURPOSE: Immune suppression is common in patients with advanced breast cancer but the mechanisms underlying this phenomenon have not been sufficiently studied. In this study, we aimed to identify B7 family members that were able to predict the immune...

Cite
Yang L, Cai Y, Zhang D, et al. miR-195/miR-497 Regulate . J Breast Cancer. 2018;21(4):371-381doi: 10.4048/jbc.2018.21.e60.
Yang, L., Cai, Y., Zhang, D., Sun, J., Xu, C., Zhao, W., Jiang, W., & Pan, C. (2018). miR-195/miR-497 Regulate . Journal of breast cancer, 21(4), 371-381. https://doi.org/10.4048/jbc.2018.21.e60
Yang, Lianzhou, et al. "miR-195/miR-497 Regulate ." Journal of breast cancer vol. 21,4 (2018): 371-381. doi: https://doi.org/10.4048/jbc.2018.21.e60
Yang L, Cai Y, Zhang D, Sun J, Xu C, Zhao W, Jiang W, Pan C. miR-195/miR-497 Regulate . J Breast Cancer. 2018 Dec;21(4):371-381. doi: 10.4048/jbc.2018.21.e60. Epub 2018 Dec 26. PMID: 30607158; PMCID: PMC6310715.
Copy Download .nbib Format: NLM
Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.

European journal of haematology

Mortensen JB, Monrad I, Enemark MB, Ludvigsen M, Kamper P, Bjerre M, d'Amore F.
PMID: 33721375
Eur J Haematol. 2021 Jul;107(1):81-91. doi: 10.1111/ejh.13621. Epub 2021 Apr 12.

BACKGROUND: The programmed cell death protein 1 (PD-1) and its ligand 1 and 2 (PD-L1/PD-L2) regulate the immune system, and the checkpoint pathway can be exploited by malignant cells to evade anti-tumor immune response. Soluble forms (sPD-1/sPD-L1/sPD-L2) exist in...

Cite
Mortensen JB, Monrad I, Enemark MB, et al. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies. Eur J Haematol. 2021;107(1):81-91doi: 10.1111/ejh.13621.
Mortensen, J. B., Monrad, I., Enemark, M. B., Ludvigsen, M., Kamper, P., Bjerre, M., & d'Amore, F. (2021). Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies. European journal of haematology, 107(1), 81-91. https://doi.org/10.1111/ejh.13621
Mortensen, Julie B, et al. "Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies." European journal of haematology vol. 107,1 (2021): 81-91. doi: https://doi.org/10.1111/ejh.13621
Mortensen JB, Monrad I, Enemark MB, Ludvigsen M, Kamper P, Bjerre M, d'Amore F. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies. Eur J Haematol. 2021 Jul;107(1):81-91. doi: 10.1111/ejh.13621. Epub 2021 Apr 12. PMID: 33721375.
Copy Download .nbib Format: NLM
The PD-1-PD-L1 Axis in Chronic Obstructive Pulmonary Disease.

American journal of respiratory and critical care medicine

Stoll P, Virchow JC, Lommatzsch M.
PMID: 27585389
Am J Respir Crit Care Med. 2016 Sep 01;194(5):644. doi: 10.1164/rccm.201604-0752LE.

No abstract available.

Cite
Stoll P, Virchow JC, Lommatzsch M. The PD-1-PD-L1 Axis in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2016;194(5):644doi: 10.1164/rccm.201604-0752LE.
Stoll, P., Virchow, J. C., & Lommatzsch, M. (2016). The PD-1-PD-L1 Axis in Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine, 194(5), 644. https://doi.org/10.1164/rccm.201604-0752LE
Stoll, Paul, et al. "The PD-1-PD-L1 Axis in Chronic Obstructive Pulmonary Disease." American journal of respiratory and critical care medicine vol. 194,5 (2016): 644. doi: https://doi.org/10.1164/rccm.201604-0752LE
Stoll P, Virchow JC, Lommatzsch M. The PD-1-PD-L1 Axis in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2016 Sep 01;194(5):644. doi: 10.1164/rccm.201604-0752LE. PMID: 27585389.
Copy Download .nbib Format: NLM
CX-072 (pacmilimab), a Probody .

Journal for immunotherapy of cancer

Naing A, Thistlethwaite F, De Vries EGE, Eskens FALM, Uboha N, Ott PA, LoRusso P, Garcia-Corbacho J, Boni V, Bendell J, Autio KA, Randhawa M, Durm G, Gil-Martin M, Stroh M, Hannah AL, Arkenau HT, Spira A.
PMID: 34301809
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002447.

BACKGROUND: ProbodyMETHODS: In the dose-escalation phase of this multicenter, open-label study (NCT03013491), adults with advanced solid tumors (naive to programmed-death-1/PD-L1 or cytotoxic T-lymphocyte-associated antigen 4 inhibitors) were enrolled into one of seven dose-escalation cohorts, with pacmilimab administered intravenously every...

Cite
Naing A, Thistlethwaite F, De Vries EGE, et al. CX-072 (pacmilimab), a Probody . J Immunother Cancer. 2021;9(7)doi: 10.1136/jitc-2021-002447.
Naing, A., Thistlethwaite, F., De Vries, E. G. E., Eskens, F. A. L. M., Uboha, N., Ott, P. A., LoRusso, P., Garcia-Corbacho, J., Boni, V., Bendell, J., Autio, K. A., Randhawa, M., Durm, G., Gil-Martin, M., Stroh, M., Hannah, A. L., Arkenau, H. T., & Spira, A. (2021). CX-072 (pacmilimab), a Probody . Journal for immunotherapy of cancer, 9(7), . https://doi.org/10.1136/jitc-2021-002447
Naing, Aung, et al. "CX-072 (pacmilimab), a Probody ." Journal for immunotherapy of cancer vol. 9,7 (2021). doi: https://doi.org/10.1136/jitc-2021-002447
Naing A, Thistlethwaite F, De Vries EGE, Eskens FALM, Uboha N, Ott PA, LoRusso P, Garcia-Corbacho J, Boni V, Bendell J, Autio KA, Randhawa M, Durm G, Gil-Martin M, Stroh M, Hannah AL, Arkenau HT, Spira A. CX-072 (pacmilimab), a Probody . J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002447. PMID: 34301809; PMCID: PMC8311335.
Copy Download .nbib Format: NLM
CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.

Journal for immunotherapy of cancer

Peng QH, Wang CH, Chen HM, Zhang RX, Pan ZZ, Lu ZH, Wang GY, Yue X, Huang W, Liu RY.
PMID: 33579737
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001638.

BACKGROUND: CKLF-like MARVEL transmembrane domain-containing 6 (CMTM6), a programmed death-ligand 1 (PD-L1) regulator, is widely expressed in various tumors and regulates the immune microenvironment. However, its prognostic value remains controversial, and the roles of CMTM6 in colorectal cancer (CRC)...

Cite
Peng QH, Wang CH, Chen HM, et al. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. J Immunother Cancer. 2021;9(2)doi: 10.1136/jitc-2020-001638.
Peng, Q. H., Wang, C. H., Chen, H. M., Zhang, R. X., Pan, Z. Z., Lu, Z. H., Wang, G. Y., Yue, X., Huang, W., & Liu, R. Y. (2021). CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. Journal for immunotherapy of cancer, 9(2), . https://doi.org/10.1136/jitc-2020-001638
Peng, Qi-Hua, et al. "CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer." Journal for immunotherapy of cancer vol. 9,2 (2021). doi: https://doi.org/10.1136/jitc-2020-001638
Peng QH, Wang CH, Chen HM, Zhang RX, Pan ZZ, Lu ZH, Wang GY, Yue X, Huang W, Liu RY. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001638. PMID: 33579737; PMCID: PMC7883863.
Copy Download .nbib Format: NLM
Reply: The PD-1-PD-L1 Axis in Chronic Obstructive Pulmonary Disease.

American journal of respiratory and critical care medicine

Staples KJ, Wilkinson TM.
PMID: 27585390
Am J Respir Crit Care Med. 2016 Sep 01;194(5):644-5. doi: 10.1164/rccm.201604-0863LE.

No abstract available.

Cite
Staples KJ, Wilkinson TM. Reply: The PD-1-PD-L1 Axis in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2016;194(5):644-5doi: 10.1164/rccm.201604-0863LE.
Staples, K. J., & Wilkinson, T. M. (2016). Reply: The PD-1-PD-L1 Axis in Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine, 194(5), 644-5. https://doi.org/10.1164/rccm.201604-0863LE
Staples, Karl J, and Wilkinson, Tom M A. "Reply: The PD-1-PD-L1 Axis in Chronic Obstructive Pulmonary Disease." American journal of respiratory and critical care medicine vol. 194,5 (2016): 644-5. doi: https://doi.org/10.1164/rccm.201604-0863LE
Staples KJ, Wilkinson TM. Reply: The PD-1-PD-L1 Axis in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2016 Sep 01;194(5):644-5. doi: 10.1164/rccm.201604-0863LE. PMID: 27585390.
Copy Download .nbib Format: NLM
PD-L1 IHC assays in melanoma.

Histopathology

Abdul Karim L, Wang P, Chahine J, Kallakury B.
PMID: 28122123
Histopathology. 2017 Jun;70(7):1177-1179. doi: 10.1111/his.13174. Epub 2017 Mar 20.

No abstract available.

Cite
Abdul Karim L, Wang P, Chahine J, et al. PD-L1 IHC assays in melanoma. Histopathology. 2017;70(7):1177-1179doi: 10.1111/his.13174.
Abdul Karim, L., Wang, P., Chahine, J., & Kallakury, B. (2017). PD-L1 IHC assays in melanoma. Histopathology, 70(7), 1177-1179. https://doi.org/10.1111/his.13174
Abdul Karim, Lina, et al. "PD-L1 IHC assays in melanoma." Histopathology vol. 70,7 (2017): 1177-1179. doi: https://doi.org/10.1111/his.13174
Abdul Karim L, Wang P, Chahine J, Kallakury B. PD-L1 IHC assays in melanoma. Histopathology. 2017 Jun;70(7):1177-1179. doi: 10.1111/his.13174. Epub 2017 Mar 20. PMID: 28122123.
Copy Download .nbib Format: NLM
Human Rhinovirus Infection Enhances the Th2 Environment in Allergic and Non-allergic Patients with Chronic Rhinosinusitis.

Clinical and experimental otorhinolaryngology

Ko YK, Zhang YL, Wee JH, Han DH, Kim HJ, Rhee CS.
PMID: 32911880
Clin Exp Otorhinolaryngol. 2021 May;14(2):217-224. doi: 10.21053/ceo.2020.00444. Epub 2020 Sep 11.

OBJECTIVES: This study was conducted to determine whether patients with allergic rhinitis might be more susceptible to human rhinovirus (HRV) infection and whether the effects of infection on the elicited immune responses are different in allergic and non-allergic patients...

Cite
Ko YK, Zhang YL, Wee JH, et al. Human Rhinovirus Infection Enhances the Th2 Environment in Allergic and Non-allergic Patients with Chronic Rhinosinusitis. Clin Exp Otorhinolaryngol. 2020;14(2):217-224doi: 10.21053/ceo.2020.00444.
Ko, Y. K., Zhang, Y. L., Wee, J. H., Han, D. H., Kim, H. J., & Rhee, C. S. (2021). Human Rhinovirus Infection Enhances the Th2 Environment in Allergic and Non-allergic Patients with Chronic Rhinosinusitis. Clinical and experimental otorhinolaryngology, 14(2), 217-224. https://doi.org/10.21053/ceo.2020.00444
Ko, Young-Kyung, et al. "Human Rhinovirus Infection Enhances the Th2 Environment in Allergic and Non-allergic Patients with Chronic Rhinosinusitis." Clinical and experimental otorhinolaryngology vol. 14,2 (2021): 217-224. doi: https://doi.org/10.21053/ceo.2020.00444
Ko YK, Zhang YL, Wee JH, Han DH, Kim HJ, Rhee CS. Human Rhinovirus Infection Enhances the Th2 Environment in Allergic and Non-allergic Patients with Chronic Rhinosinusitis. Clin Exp Otorhinolaryngol. 2021 May;14(2):217-224. doi: 10.21053/ceo.2020.00444. Epub 2020 Sep 11. PMID: 32911880; PMCID: PMC8111390.
Copy Download .nbib Format: NLM
Can We MIRror the Efficacy of Immune Checkpoints With miRNAs?.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Alexander M, Wrangle J.
PMID: 33148406
J Thorac Oncol. 2020 Nov;15(11):1703-1704. doi: 10.1016/j.jtho.2020.08.007. Epub 2020 Oct 23.

No abstract available.

Cite
Alexander M, Wrangle J. Can We MIRror the Efficacy of Immune Checkpoints With miRNAs?. J Thorac Oncol. 2020;15(11):1703-1704doi: 10.1016/j.jtho.2020.08.007.
Alexander, M., & Wrangle, J. (2020). Can We MIRror the Efficacy of Immune Checkpoints With miRNAs?. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 15(11), 1703-1704. https://doi.org/10.1016/j.jtho.2020.08.007
Alexander, Mariam, and Wrangle, John. "Can We MIRror the Efficacy of Immune Checkpoints With miRNAs?." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 15,11 (2020): 1703-1704. doi: https://doi.org/10.1016/j.jtho.2020.08.007
Alexander M, Wrangle J. Can We MIRror the Efficacy of Immune Checkpoints With miRNAs?. J Thorac Oncol. 2020 Nov;15(11):1703-1704. doi: 10.1016/j.jtho.2020.08.007. Epub 2020 Oct 23. PMID: 33148406.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 25 entries